The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Ceralasertib (cerala) + olaparib (ola) in patients (pts) with homologous recombination repair (HRR)-deficient platinum-sensitive relapsed ovarian cancer (OC) after progression on prior PARP inhibitor (PARPi) treatment (tx).
 
Rene Roux
No Relationships to Disclose
 
Sophie Postel-Vinay
Consulting or Advisory Role - Amgen (Inst); Daiichi Sankyo (Inst); EPICs therapeutics
Research Funding - Amgen (Inst); AstraZeneca (Inst); Daiichi Sankyo/Lilly (Inst); GlaxoSmithKline/Tesaro (Inst); Roche/imCORE (Inst)
 
Mario Campone
Honoraria - Pfizer (Inst)
Consulting or Advisory Role - Pfizer (Inst)
Speakers' Bureau - Lilly (Inst); Novartis (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Novartis; Pfizer
 
Antoine Italiano
Honoraria - Bayer; Daiichi Sankyo; Epizyme; IPSEN; Lilly; Novartis; Roche
Consulting or Advisory Role - Bayer; Daiichi Sankyo; Epizyme; Immune Design; Lilly; Roche
Research Funding - AstraZeneca/MedImmune; Bayer; Merck Serono; Merck Serono; MSD Oncology; PharmaMar; Roche
Patents, Royalties, Other Intellectual Property - BMS
 
Claire Friedman
Honoraria - GlaxoSmithKline; MJH Healthcare Holdings, LLC
Consulting or Advisory Role - AADi; Arch Oncology; Bristol Myers Squibb; Loxo/Lilly
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo/UCB Japan (Inst); Genentech (Inst); Hotspot Therapeutics (Inst); Immunocore (Inst); Loxo/Lilly (Inst); Marengo Therapeutics (Inst); Merck (Inst); Seagen (Inst); Volastra Therapeutics (Inst)
Travel, Accommodations, Expenses - Puma Biotechnology
(OPTIONAL) Uncompensated Relationships - Genentech; Marengo Therapeutics; Merck
 
Myong Cheol Lim
Consulting or Advisory Role - AstraZeneca; Boryung; CKD pharm; Genexine; GI Innovation; Hospicare; Takeda
Research Funding - Abbvie (Inst); Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); BeiGene (Inst); Cellid (Inst); CKD pharm (Inst); Clovis Oncology (Inst); Eisai (Inst); Genexine (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Merck (Inst); MSD (Inst); OncoQuest (Inst); Pfizer (Inst); Roche (Inst)
 
Rowan Miller
Consulting or Advisory Role - AZD; Clovis Oncology; Ellipses Pharma; GlaxoSmithKline; Merck KGaA; Roche
Speakers' Bureau - AZD; Clovis Oncology; GlaxoSmithKline; Roche
Travel, Accommodations, Expenses - AstraZeneca; Tesaro
 
Geoffrey Shapiro
Consulting or Advisory Role - Bicycle Therapeutics; Merck Serono; Xinthera
Research Funding - Bristol-Myers Squibb/Medarex (Inst); Lilly (Inst); Merck (Inst); Merck Serono (Inst); Pfizer (Inst); Tango Therapeutics (Inst)
Patents, Royalties, Other Intellectual Property - Patent # 10,934,593 B2 Compositions and methods for predicting response and resistance to CDK4/6 inhibition; Patent #: 9872874 Title: Dosage regimen for sapacitabine and seliciclib Issue Date: 1/23/2018
 
Matthew Krebs
Honoraria - Roche
Consulting or Advisory Role - Achilles Therapeutics; Bayer; Guardant Health; Janssen; OM Pharma; Roche; Seagen; Zai lab
Speakers' Bureau - BMS; Eisai; Guardant Health; Janssen; Roche
Research Funding - Novartis (Inst); Roche (Inst)
Travel, Accommodations, Expenses - AstraZeneca; BerGenBio; BerGenBio; BMS; Immutep; Janssen; Roche; Roche; Zai Lab
 
Graeme Parr
Employment - AstraZeneca/MedImmune
Stock and Other Ownership Interests - AstraZeneca/MedImmune
 
Conor Norris
Employment - AstraZeneca/MedImmune
Stock and Other Ownership Interests - AstraZeneca/MedImmune
 
Daniel Slade
Employment - AstraZeneca
 
Natalia Lukashchuk
Employment - AstraZeneca
Stock and Other Ownership Interests - AstraZeneca
Research Funding - AstraZeneca
Travel, Accommodations, Expenses - AstraZeneca
 
Jyoti Nehra
Employment - AstraZeneca/MedImmune
Stock and Other Ownership Interests - AstraZeneca/MedImmune
 
Olga Murina
Employment - AstraZeneca/MedImmune
Stock and Other Ownership Interests - AstraZeneca/MedImmune
 
Edit Lukacs
Employment - AstraZeneca/MedImmune
Stock and Other Ownership Interests - AstraZeneca/MedImmune
 
Isabelle Ray-Coquard
Honoraria - Abbvie; Advaxis; AGENUS; Amgen; AstraZeneca; Bristol-Myers Squibb; Clovis Oncology; Daiichi Sankyo; DECIPHERA; Genmab; GlaxoSmithKline; IMMUNOCORE; Immunogen; Macrogenics; MERSANA; MSD Oncology; Novartis; OxOnc; Pfizer; PharmaMar; PMV Pharma; Roche; Seagen; Sutro Biopharma; Tesaro
Consulting or Advisory Role - Abbvie; AGENUS; AstraZeneca; Blueprint Medicines; BMS; Bristol-Myers Squibb; Clovis Oncology; Corcept Therapeutics; Daichi; Deciphera; Eisai; Genmab; GlaxoSmithKline; Immunocore; Immunogen; Incyte; Macrogenics; Mersana; MSD Oncology; Netris Pharma; Novartis; Novocure; Ose pharma; Pfizer; PharmaMar; Roche; Scorpion Therapeutics; seagen; Seagen; Sutro Biopharma; Tesaro
Research Funding - BMS; MSD Oncology; Roche/Genentech (Inst)
Travel, Accommodations, Expenses - Advaxis; AstraZeneca; BMS; Clovis Oncology; Clovis Oncology; GlaxoSmithKline; PharmaMar; Roche; Tesaro
(OPTIONAL) Uncompensated Relationships - Arcagy-Gineco; Belgium health authorities; French National Cancer Institute (INCA); GERMAN health authorities; ITALIAN HEALTH AUTORITIES